<DOC>
	<DOCNO>NCT00190333</DOCNO>
	<brief_summary>This Phase III , multicenter , randomize , double-blind , placebo-controlled study evaluate efficacy escitalopram ( 30 mg/day ) two parallel group ( randomization ratio , escitalopram 2/placebo 1 ) .</brief_summary>
	<brief_title>Serotonin Transporter Inhibitor Escitalopram Pulmonary Hypertension</brief_title>
	<detailed_description>Primary objective : evaluate efficacy oral escitalopram dosage 30 mg/day 16 week 6-minute walking test patient pulmonary hypertension .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Serotonin</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Subjects meet criterion list consider study inclusion : Male female old 18 year age Meeting World Health Organization ( WHO ) criteria pulmonary hypertension ( mean pulmonary arterial pressure [ PAP ] &gt; 25 mmHg rest pulmonary capillary wedge pressure &lt; 15 mmHg right heart catheterization ) : primary pulmonary hypertension ( sporadic familial ) , pulmonary hypertension associate connective tissue disease , pulmonary hypertension associate HIV infection , pulmonary hypertension associate use appetite suppressant toxic compound , pulmonary hypertension associate shunt congenital heart defect surgically treat Class II III NYHA classification scheme With 6minute walk test distance 40 % 80 % theoretical value ( approximately 50 480 ) On conventional treatment , change treatment last month precede study . Conventional treatment include calcium antagonist beraprost . Subject consent participate study . Subjects follow clinical feature include study : Pulmonary hypertension relate aortic mitral valve disease , extrinsic pulmonary vein compression Pulmonary hypertension relate hypoxia respiratory disease total lung capacity &lt; 70 % Tiffeneau index &lt; 60 % upon test within last 6 month ( chronic obstructive lung disease , interstitial disease , sleep apnea syndrome , alveolar hypoventilation , chronic exposure high altitude , neonatal lung disease , alveolar capillary dysplasia ) Pulmonary hypertension associate portal hypertension Pulmonary hypertension secondary chronic thrombosis and/or embolism ( occlusion proximal distal pulmonary artery thrombosis ) In 6minute walk test , inability walk 6 minute , reason , walk distance le 50 Pregnancy , lactation , woman childbearing potential ( need , effective contraception prescribe ) History hypersensitivity citalopram medication structurally related citalopram Treatment another investigational drug within 3 month precede study inclusion Cardiovascular , hepatic , neurological endocrine disease clinically significant , significant disease may interfere study protocol interpretation study finding History drug alcohol abuse Liver failure ( except abnormality relate right ventricular failure ) Kidney failure Mental status prevent patient understanding nature , objective , possible consequence study Non stabilize psychiatric disorder Subject unable comply protocolrelated constraint ( e.g. , uncooperative , unable attend followup visit , probably unable complete study ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>pulmonary hypertension</keyword>
	<keyword>6 minute walk test</keyword>
	<keyword>serotonin</keyword>
	<keyword>primary associate pulmonary hypertension</keyword>
</DOC>